Oncology drugs enter the US market faster than in Europe but cost more

摘要

ONCOLOGY DRUGS GET APPROVED faster in the United States than in European countries, but they also costmore in the United States, according to a report released July 10. The report, from the Tufts Center for the Study of Drug Development, found that between 2000 and 2011, the US Food and Drug Administration (FDA) approved 40 new oncology drugs, one-third more than the 30 approved by the European Medicines Agency (EMA). Also, of the 28 drugs approved by both the FDA and the EMA, all were approved first by the FDA.